Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Digestive System Neoplasms × anlotinib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 34 Small Cell Lung Carcinoma 15 Breast Neoplasms 12 Sarcoma 10 Lung Neoplasms 9 Thyroid Neoplasms 6 Stomach Neoplasms 6 Esophageal Squamous Cell Carcinoma 6 NSCLC 5 Carcinoma, Hepatocellular 5 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Esophageal Neoplasms 4 Carcinoma 4 Neoplasms 3 Nasopharyngeal Carcinoma 3 Glioma 3 Colorectal Neoplasms 3 Cholangiocarcinoma 3 Brain Neoplasms 3 Biliary Tract Neoplasms 3 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Triple Negative Breast Neoplasms 2 Recurrence 2 Platinum-resistant Ovarian Cancer 2 Pheochromocytoma 2 Paraganglioma 2 Ovarian Diseases 2 Non-squamous Non-small Cell Lung Cancer 2

Interventions

Capecitabine 6 Irinotecan 5 Fluorouracil 5 Oxaliplatin 4 Leucovorin 4 apatinib 3 Sorafenib 3 Gemcitabine 3 Cisplatin 3 Bevacizumab 3 tislelizumab 2 Sunitinib 2 Radiotherapy 2 Immune Checkpoint Inhibitors 2 Cyclophosphamide 2 Aspirin 2 Ascorbic Acid 2 130-nm albumin-bound paclitaxel 2 spartalizumab 1 sintilimab 1 regorafenib 1 pyrotinib 1 pemigatinib 1 pembrolizumab 1 lutetium Lu 177 dotatate 1 huachansu 1 halofantrine 1 guadecitabine 1 genexol-PM 1 fludarabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05262335 2023-11-28

ALTER-G-001

Ruijin Hospital

Phase 2 Unknown

Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡